Group 1 - The company, Jingfang Pharmaceutical-B (02595), plans to conduct an initial public offering (IPO) from September 11 to September 16, 2025, aiming to globally offer 77.6 million H-shares, with approximately 10% allocated for public sale in Hong Kong and 90% for international sale [1] - The offering price is set at HKD 20.39 per share, with a minimum purchase of 200 shares, and trading on the Hong Kong Stock Exchange is expected to commence on September 19, 2025 [1] - The company has established a product pipeline that includes eight candidate products, five of which are currently in clinical development, focusing on treatments targeting RAS family members, which are key regulators in cell signaling [1] Group 2 - The total net proceeds from the global offering are estimated to be approximately HKD 1.4436 billion, with about 71% allocated for the further development of core products GFH925 and GFH375 [2] - Approximately 19% of the net proceeds will be used for the development of other candidate products, including GFH312, GFS202A, GFH276, GFS784, and other preclinical candidates [2] - About 10% of the net proceeds will be allocated for the company's working capital and other general corporate purposes [2] Group 3 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares amounting to USD 100 million under certain conditions [3] - Notable cornerstone investors include RTW funds, TruMed, OrbiMed, UBS Asset Management, Vivo funds, and several other investment entities [3] - These cornerstone investors are expected to play a significant role in the success of the IPO by providing substantial financial backing [3]